About CHIKV VLP CHIKV VLP is an adjuvanted VLP recombinant protein vaccine for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older.

Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...

CHIKV VLP is an adjuvanted VLP recombinant protein vaccine for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. Because VLPs ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in ...

Temperature Controlled Packaging Solution NEW YORK, DE, UNITED STATES, February 6, 2025 /EINPresswire / -- The temperature-controlled packagin ...

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

For each virus we expressed a small panel of recombinant variants of ... that possess class I membrane fusion proteins. We established a workflow to expedite the development of a pre-fusion stabilized ...

Subunit vaccines are currently plagued by the difficulty of expressing recombinant viral and protozoan membrane antigens in their natural structural state, as well as the production of misfolded or ...